These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34880628)

  • 1. Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review.
    Xiao C; Xu F; Wang R; Liang Q; Shen K; Xu J; Liu L
    Onco Targets Ther; 2021; 14():5363-5372. PubMed ID: 34880628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.
    Jin M; Cai J; Wang X; Zhang T; Zhao Y
    Cancer Biol Ther; 2018; 19(12):1088-1092. PubMed ID: 30110192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
    Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
    Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report.
    Deng L; Wang Y; Lu W; Liu Q; Wu J; Jin J
    Onco Targets Ther; 2017; 10():1521-1525. PubMed ID: 28352185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706).
    Zhao H; Yao W; Min X; Gu K; Yu G; Zhang Z; Cui J; Miao L; Zhang L; Yuan X; Fang Y; Fu X; Hu C; Zhu X; Fan Y; Yu Q; Wu G; Jiang O; Du X; Liu J; Gu W; Hou Z; Wang Q; Zheng R; Zhou X; Zhang L
    J Thorac Oncol; 2021 Sep; 16(9):1533-1546. PubMed ID: 34033974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
    Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
    Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
    Lan CY; Wang Y; Xiong Y; Li JD; Shen JX; Li YF; Zheng M; Zhang YN; Feng YL; Liu Q; Huang HQ; Huang X
    Lancet Oncol; 2018 Sep; 19(9):1239-1246. PubMed ID: 30082170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
    Kong Q; Wang XY; Jiang RC; Ba Y; Li K
    Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study.
    Zhang J; Li A; Jiang Q; Zheng F; Zhu H
    Drug Des Devel Ther; 2019; 13():3913-3918. PubMed ID: 31814710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer.
    Zhang Z; Zhang Y; Luo F; Ma Y; Fang W; Zhan J; Li S; Yang Y; Zhao Y; Hong S; Zhou T; Zhang Y; Zhao S; Huang Y; Zhao H; Zhang L
    Clin Transl Med; 2020 Jun; 10(2):e33. PubMed ID: 32508029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature.
    Zhang C; Yu GM; Zhang M; Wu W; Gong LB
    Medicine (Baltimore); 2020 Jan; 99(3):e18892. PubMed ID: 32011517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer.
    Wu Y; Zhang X; Li L; Yang W; Yan Z; Gu C; Zhang Z; Zhou J; Liu L; Ye M; Meng Y
    Onco Targets Ther; 2022; 15():973-979. PubMed ID: 36118677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.
    Chen W; Li Z; Zheng Z; Wu X
    Cancer Med; 2020 Aug; 9(16):5899-5907. PubMed ID: 32627959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China.
    Peng W; Zhang F; Wang Z; Li D; He Y; Ning Z; Sheng L; Wang J; Xia X; Yu C; Wang Z; Zhao Y; Liang H; Hu B; Sun C; Wang D; Cheng Y; Pan M; Xia L; Guo X; Zhang Y; Hu Z; Li X; Lu L; Zhang J; Qian H; Xie H; Sun G
    Cancer Manag Res; 2020; 12():6977-6985. PubMed ID: 32821164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
    Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
    Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients.
    Yang M; Liu X; Zhang C; Liao F; Li Z; Luo X; Sun Y; Chen C
    Cancer Manag Res; 2019; 11():8869-8876. PubMed ID: 31632146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review.
    Wang Y; Li W; Jing N; Meng X; Zhou S; Zhu Y; Xu J; Tao R
    Cancer Biol Ther; 2020 Jul; 21(7):583-589. PubMed ID: 32212907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial.
    Zhou N; Zhang C; Liu D; Liu K; Wang G; Zhu H; Zhang J; Jiang M; Liu N; Zhang X
    Oncologist; 2021 Mar; 26(3):e374-e381. PubMed ID: 33244809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.